nach oben

Annals of Hematology

Erschienen in:

21.01.2019 | Original Article

Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies

verfasst von: Yu-Lin Zhang, Yan Zhu, Qing Xiao, Li Wang, Lin Liu, Xiao-Hua Luo

Erschienen in: Annals of Hematology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Cytomegalovirus (CMV) infection and primary disease relapse remain challenging problems after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We sought to assess the association between CMV infection and disease relapse after transplantation. PubMed, EMBASE, the Cochrane Library, SCI, and Chinese Biomedicine Databases were searched up to July 1, 2018, for all studies that investigate pre-transplant CMV serostatus, CMV replication, and primary disease relapse in allo-HSCT patients with hematologic malignancies. Meta-analysis of 24 eligible cohort studies showed a significantly lower relapse risk after allo-HSCT in patients with CMV replication in acute myeloid leukemia (AML) (HR = 0.64, 95% CI, 0.50–0.83; P < 0.001) subgroup. However, CMV replication was associated with increased non-relapse mortality (NRM) in AML patients (HR = 1.64, 95% CI, 1.46–1.85; P < 0.001), but not associated with overall survival (OS) or graft-versus-host disease for AML patients (P > 0.05). There was no association between pre-transplant CMV serostatus and disease relapse, although D−/R− was associated with better OS in acute leukemia patients (HR = 0.89, 95% CI, 0.83–0.96; P = 0.003). In AML patients, CMV replication may be a protective predictor against disease relapse, although the potential benefit of CMV replication is offset by increased NRM.

Nur mit Berechtigung zugänglich

Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64(1):87–91

Ljungman P (2007) Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol 20:209–217CrossRefPubMed

Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, Halter J, Heim D, Tichelli A, Gratwohl A (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16:1309–1314CrossRefPubMed

Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478–488CrossRefPubMed

Lacey SF, Gallez-Hawkins G, Crooks M, Martinez J, Senitzer D, Forman SJ, Spielberger R, Zaia JA, Diamond DJ (2002) Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 74:722–732CrossRefPubMed

Luo X-H, Huang X-J, Liu K-Y, Xu L-P, Liu D-H (2010) Protective immunity transferred by infusion of cytomegalovirus-specific CD8+ T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:994–1004CrossRefPubMed

Luo XH, Huang XJ, Li D, Liu KY, Xu LP, Liu DH (2013) Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts. Transpl Infect Dis 15:22–33CrossRefPubMed

Luo X-H, Chang Y-J, Huang X-J (2014) Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation. J Immunol Res 2014:1–12CrossRef

Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118:1402–1412CrossRefPubMed

10.

Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122:1316–1324CrossRefPubMedPubMedCentral

11.

Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ (2009) Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 15:54–60CrossRefPubMedPubMedCentral

12.

Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 20:46–52CrossRefPubMed

13.

Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ (2004) Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10:49–57CrossRefPubMed

14.

Vítek A, Lukášová M, Chudomel V, Májský A, Souček J, Kobylka P, Kořínková P, Loudová M, Dobrovolná M, Matějková E (2012) Transplantation of haematopoietic cells and its role in the treatment of haematopoiesis during the last 25 years. Vnitrni Lekarstvi 58:46–55

15.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentral

16.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed

17.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed

18.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

19.

Spruance SL, Reid JE, Grace M, Samore M (2004) Hazard ratio in clinical trials. Antimicrob Agents Chemother 48:2787–2792CrossRefPubMedPubMedCentral

20.

Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463CrossRefPubMed

21.

Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P. 2011. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In Ottawa, Ontario, Canada: Ottawa Hospital Research Institute. Accessed at www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 30 Sept 2018

22.

Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young J-A, Weisdorf DH, Cooley S, Miller JS, Verneris MR (2010) Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 16:215–222CrossRefPubMed

23.

Broers AE, van der Holt R, van Esser JW, Gratama J-W, Henzen-Logmans S, Kuenen-Boumeester V, Löwenberg B, Cornelissen JJ (2000) Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation. Blood 95:2240–2245PubMed

24.

Chen Y, Xu L-P, Liu K-Y, Chen H, Chen Y-H, Zhang X-H, Wang Y, Wang F-R, Han W, Wang J-Z (2016) Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol 75:10–15CrossRefPubMed

25.

Inagaki J, Noguchi M, Kurauchi K, Tanioka S, Fukano R, Okamura J (2016) Effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia. Biol Blood Marrow Transplant 22:300–306CrossRefPubMed

26.

Ito S, Pophali P, Wu C, Koklanaris EK, Superata J, Fahle GA, Childs R, Battiwalla M, Barrett AJ (2013) CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 48:1313–1316CrossRefPubMedPubMedCentral

27.

Jacobsen N, Badsberg JH, Lönnqvist B, Ringden O, Volin L, Rajantie J, Nikoskelainen J, Keiding N (1990) Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 5:413–418PubMed

28.

Jang JE, Kim SJ, Cheong J-W, Hyun SY, Kim YD, Kim YR, Kim JS, Min YH (2015) Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 94:275–282CrossRefPubMed

29.

Jeljeli M, Khourouj GE, Porcher R, Fahd M, Leveillé S, Yakouben K, Ouachée-Chardin M, LeGoff J, Cordeiro DJ, Pédron B (2014) Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. Br J Haematol 166:229–239CrossRefPubMed

30.

Kim DH, Won DI, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB (2006) Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation. Transplantation 81:101–108CrossRefPubMed

31.

Koldehoff M, Ross SR, Dührsen U, Beelen DW, Elmaagacli AH (2017) Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. Leuk Lymphoma 58:822–833CrossRefPubMed

32.

Lin X, Ou Y, Long H, Huang Y, Song C, Lu Z, Guo K, Wu B, Xu J (2016) Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia. Zhonghua nei ke za zhi 55:107–110PubMed

33.

Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L, Montefusco V, Carniti C, Sarina B, Patriarca F (2014) Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20:885–890CrossRefPubMed

34.

Niu X, He H, Zhou R, Xu X (2015) Impact of human cytomegalovirus viremia on relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients. Zhonghua Yi Xue Za Zhi 95:123–125PubMed

35.

Ramanathan M, Teira P, Battiwalla M, Barrett J, Ahn K, Chen M, Green J, Laughlin M, Lazarus H, Marks D (2016) Impact of early CMV reactivation in cord blood stem cell recipients in the current era. Bone Marrow Transplant 51:1113–1120CrossRefPubMedPubMedCentral

36.

Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A (2013) CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122:3359–3364CrossRefPubMed

37.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 21:2008–2016CrossRefPubMed

38.

Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN (2016) Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427–2438

39.

Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kato S, Kasahara S, Iseki T, Yamaguchi T, Tojo A (2008) Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol 80:251–257CrossRefPubMed

40.

Yoon J-H, Lee S, Kim H-J, Jeon Y-W, Lee S-E, Cho B-S, Lee D-G, Eom K-S, Kim Y-J, Min C-K (2016) Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. Oncotarget 7:17230PubMedPubMedCentral

41.

Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg J, Hardy N, Kroeger N, Leis J, Levine J (2010) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:1467–1503CrossRefPubMedPubMedCentral

42.

Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers ME, Mielcarek M (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23:1993–2003CrossRefPubMed

43.

Ishaqi M, Afzal S, Dupuis A, Doyle J, Gassas A (2008) Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 41:245–252CrossRefPubMed

44.

Luo X, Chang Y, Xu L, Liu D, Liu K, Huang X (2009) The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 43:29–36CrossRefPubMed

45.

Nemecek E, Gooley T, Woolfrey A, Carpenter P, Matthews D, Sanders J (2004) Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 34:799–806CrossRefPubMedPubMedCentral

46.

Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS (2007) Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110:409–417CrossRefPubMedPubMedCentral

47.

Huang X-J, Zhu H-H, Chang Y-J, Xu L-P, Liu D-H, Zhang X-H, Jiang B, Jiang Q, Jiang H, Chen Y-H (2012) The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute myeloid leukemia in first complete remission. Blood 119:5584–5590CrossRefPubMed

48.

Tchao NK, Turka LA (2012) Lymphodepletion and homeostatic proliferation: implications for transplantation. Am J Transplant 12:1079–1090CrossRefPubMed

49.

Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, Bredius RG, van Tol MJ, Lankester AC (2014) Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20:655–661CrossRefPubMed

50.

Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, Boeckh M (2003) Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy and subclinical reactivation. Blood 102:3060–3067CrossRefPubMed

51.

Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F (2006) Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108:1406–1412CrossRefPubMed

52.

Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PA (2001) Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97:1232–1240CrossRefPubMed

53.

Gratama JW, van Esser JW, Lamers CH, Tournay C, Löwenberg B, Bolhuis RL, Cornelissen JJ (2001) Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98:1358–1364CrossRefPubMed

54.

Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E, Kurtzberg J, Wagner JE, Kernan NA (2006) Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 12:919–927CrossRefPubMed

55.

Nachbaur D, Bonatti H, Oberaigner W, Eibl B, Kropshofer G, Gastl G, Nussbaumer W, Einsele H, Larcher C (2001) Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 358(9288):1157–1159CrossRefPubMed

56.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, John LSS, Yang T-H, Ruisaard K, Armistead PM, Mittendorf EA (2012) The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother 1997(35):309CrossRef

57.

Hermouet S, Sutton C, Rose T, Greenblatt R, Corre I, Garand R, Neves A, Bataille R, Casey J (2003) Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. Leukemia 17:185–195CrossRefPubMed

58.

Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Vergès S, Lanier LL, Weisdorf D, Miller JS (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119:2665–2674CrossRefPubMedPubMedCentral

59.

Scheper W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S, Heijhuurs S, Sebestyen Z, Gründer C, Marcu-Malina V (2013) γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 27:1328–1338CrossRefPubMed

60.

Fletcher JM, Prentice HG, Grundy JE (1998) Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J Immunol 161:2365–2374PubMed

61.

Behrendt CENR, Zaia J (2010) Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT. Biol Blood Marrow Transplant 16:133–135CrossRefPubMed

62.

Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202–213CrossRefPubMed

63.

Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A (2006) Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 176:2645–2653CrossRefPubMed

64.

Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R (2007) Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 42:563–570CrossRefPubMedPubMedCentral

65.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K (2010) Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 12:322–329CrossRefPubMed

66.

Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, Frommlet F, Gadner H, Peters C (2003) Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 31:803–808CrossRefPubMed

67.

Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872CrossRefPubMed

Titel: Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies
verfasst von: Yu-Lin Zhang
Yan Zhu
Qing Xiao
Li Wang
Lin Liu
Xiao-Hua Luo
Publikationsdatum: 21.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3585-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial

Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes

Incidence, risk factors, and clinical significance of Epstein–Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin